A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 24-Week, Phase 2 Study of Two Doses of EVP-6124 Hydrochloride or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently Receiving Memantine Medication With or Without Additional Acetylcholinesterase Inhibitor Co-Medication

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 24-Week, Phase 2 Study of Two Doses of EVP-6124 Hydrochloride or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently Receiving Memantine Medication With or Without Additional Acetylcholinesterase Inhibitor Co-Medication

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2016

At a glance

  • Drugs Encenicline (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors FORUM Pharmaceuticals
  • Most Recent Events

    • 13 Oct 2015 According to ClinicalTrials.gov, Forum has decided not to proceed with this study at this time.
    • 14 Sep 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, as per Forum Pharmaceuticals media release.
    • 14 Sep 2015 According to Forum Pharmaceuticals media release, the US FDA has placed clinical hold on all the studies investigating the effect of encenicline in Alzheimer's disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top